Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5600 Target Snapshot

MAP/microtubule affinity-regulating kinase 3 · SINGLE PROTEIN · Homo sapiens

1,969Compounds
382Assays
10Approved Drugs
1,278.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P27448. Use UniProt P27448 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P27448 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MAP/microtubule affinity-regulating kinase 3 as ChEMBL target CHEMBL5600, mapped to UniProt P27448. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MAP/microtubule affinity-regulating kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5600
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P27448
MAP/microtubule affinity-regulating kinase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether MAP/microtubule affinity-regulating kinase 3 is the right protein anchor across sources, using UniProt P27448 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMAP/microtubule affinity-regulating kinase 3
UniProt AccessionP27448
Component TypeProtein
Sequence Length753 aa

MAP/microtubule affinity-regulating kinase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as MAP/microtubule affinity-regulating kinase 3, mapped to UniProt P27448. Sequence length is 753 aa.

Mapped IDP27448
Review nameMAP/microtubule affinity-regulating kinase 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

10
Approved
6
Phase III
19
Phase II
15
Phase I
Assay Mix

Activity Type Distribution

IC50123.0
KI783.0
KD372.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.53 IC50 0.297 Preclinical
CHEMBL1980995 9.4 Ki 0.3981 Preclinical
CHEMBL3648448 9.3 IC50 0.5 Preclinical
CHEMBL388978 9.3 Kd 0.5 Preclinical
CHEMBL4532781 9.0 IC50 1.0 Preclinical
CHEMBL4569508 9.0 IC50 1.0 Preclinical
CHEMBL2000724 9.0 Ki 1.0 Preclinical
CHEMBL3884319 8.92 IC50 1.2 Preclinical
CHEMBL4550486 8.89 IC50 1.3 Preclinical
CHEMBL4528550 8.7 IC50 2.0 Preclinical
Distribution

pChEMBL Value Distribution

79
5.0
129
5.5
100
6.0
51
6.5
33
7.0
27
7.5
13
8.0
8
8.5
8
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
BARICITINIB
CHEMBL2105759
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

382
Total Assays
292
Tested Compounds
2
Assay Types
Binding — 381 assays, 142 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 258 70 6.7
assay format 51 26 7.9
subcellular format 38 37 5.9
cell-based format 34 9 6.6
Functional — 1 assays, 292 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 292 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine